Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Tetrahydrofuran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofuran SCHEMBL29033463 | 1.00 | ALDH1A1 (0.57) | — | |
| Tetrahydrofuran SCHEMBL509785 | 1.00 | — | — | |
| Tetrahydrofuran SCHEMBL20135739 | 1.00 | ALDH1A1 (0.57) | — | |
| Acetonitrile SCHEMBL35968 | 0.97 | ALDH1A1 (0.53) | — | |
| Tetrahydrofuran SCHEMBL8440428 | 0.94 | ALDH1A1 (0.50) | — | |
| Tetrahydrofuran SCHEMBL9334125 | 0.94 | ALDH1A1 (0.50) | — | |
| Tetrahydrofuran SCHEMBL8878322 | 0.91 | ALDH1A1 (0.47) | — | |
| Tetrahydrofuran SCHEMBL28215497 | 0.88 | ALDH1A1 (0.44) | — | |
| Tetrahydrofuran SCHEMBL4406239 | 0.88 | ALDH1A1 (0.44) | — | |
| Tetrahydrofuran SCHEMBL23455755 | 0.86 | ALDH1A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113820402-A | HPLC analysis method of impurity reference substance of mirabegron | 南京正大天晴制药有限公司 | 2021-12-21 | — | — | CN | claimed |
| CN-113702514-A | Method for determining atorvastatin calcium related impurity I | 天津嘉林科医有限公司 | 2021-11-26 | — | — | CN | claimed |
| CN-109406685-B | High performance liquid chromatography method for separating carfilzomib and isomers thereof | 湖南泰新医药科技有限公司 | 2021-05-25 | — | — | CN | claimed |
| EP-3619208-A1 | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | Theravance Biopharma R&D IP, LLC (US) | 2020-03-11 | — | — | EP | claimed |
| US-10251874-B2 | Crystalline forms of a JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-04-09 | — | — | US | claimed |
| CN-109580838-A | A kind of detection method of siberian cocklebur fruit capsule for treating rhinitis | 亚宝药业四川制药有限公司 | 2019-04-05 | — | — | CN | claimed |
| CN-109444292-A | A kind of HPLC method separating (R)-methychlothiazide and (S)-methychlothiazide | 南京盖斯夫医药科技有限公司 | 2019-03-08 | — | — | CN | claimed |
| CN-109406685-A | A kind of efficient liquid-phase chromatography method separating Carfilzomib and its isomers | 南京盖斯夫医药科技有限公司 | 2019-03-01 | — | — | CN | claimed |
| CN-109358138-A | A kind of efficient liquid-phase chromatography method separating (R)-bendroflumethiazide and (S)-bendroflumethiazide | 南京盖斯夫医药科技有限公司 | 2019-02-19 | — | — | CN | claimed |
| CN-109358139-A | A kind of efficient liquid-phase chromatography method separating (R)-methychlothiazide and (S)-methychlothiazide | 南京盖斯夫医药科技有限公司 | 2019-02-19 | — | — | CN | claimed |
| EP-1694685-A1 | PROCESS FOR PREPARING FORMS OF ATORVASTATIN CALCIUM SUBSTANTIALLY FREE OF IMPURITIES | Teva Pharmaceutical Industries Ltd (IL) | 2006-08-30 | — | — | EP | claimed |
| US-20060142592-A1 | Process for preparing forms of atorvastatin calcium substantially free of impurities | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-06-29 | — | — | US | claimed |
| WO-2006037125-A1 | PROCESS FOR PREPARING FORMS OF ATORVASTATIN CALCIUM SUBSTANTIALLY FREE OF IMPURITIES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-04-06 | — | — | WO | claimed |
| CN-1245198-C | Chinese medicine composition for treating diabetes and its preparing method | LUNAN PHARM CO LTD (CN) | 2006-03-15 | — | — | CN | claimed |
| CN-1709439-A | Ginseng and astragalis blood glucose loucring dorpping pill, and its preparing and detecting method | LUNAN PHARMACEUTICAL GROUP CO (CN) | 2005-12-21 | — | — | CN | claimed |
| CN-1709440-A | Ginseng and astragalis blood glucose lowering dispersion tablet and its preparing and detecting method | LUNAN PHARMACEUTICAL GROUP CO (CN) | 2005-12-21 | — | — | CN | claimed |
| CN-1709498-A | Ginseng-astragalus blood-sugar lowering soft capsule, and its preparing and detecting method | LUNAN PHARMACEUTICAL GROUP CO (CN) | 2005-12-21 | — | — | CN | claimed |
| CN-1616014-A | Chinese medicine composition for treating diabetes and its preparing method | LUNAN PHARM CO LTD (CN) | 2005-05-18 | — | — | CN | claimed |
| US-5036010-A | BMY-40800 antitumor antibiotics | BRISTOL-MYERS COMPANY (US) | 1991-07-30 | — | — | US | claimed |
| EP-0248916-A1 | Method for separation of 3S,7R-3,4,5,6,7,8,9,10,11,12-decahydro-7,14,16-trihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1-one from its 3S,7S-diastereomer | C.R.C. Compagnia di Ricerca Chimica S.p.A. (IT) | 1987-12-16 | — | — | EP | claimed |